Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
antineoplastic agent |
| gptkbp:administeredBy |
subcutaneous injection
intravenous injection intrathecal injection |
| gptkbp:affiliatedWith |
antineoplastic agent
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01BC01
|
| gptkbp:brand |
gptkb:Depocyt
Cytosar |
| gptkbp:CASNumber |
147-94-4
|
| gptkbp:chemicalClass |
gptkb:cytarabine
|
| gptkbp:contraindication |
hypersensitivity to cytarabine
|
| gptkbp:discoveredIn |
1960s
|
| gptkbp:eliminatedIn |
renal
|
| gptkbp:hasMolecularFormula |
C9H13N3O5
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ara-C
|
| gptkbp:mechanismOfAction |
inhibits DNA synthesis
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:sideEffect |
fever
nausea vomiting diarrhea neurotoxicity myelosuppression |
| gptkbp:synonym |
gptkb:Cytosar-U
cytosine arabinoside |
| gptkbp:usedFor |
treatment of acute lymphoblastic leukemia
treatment of acute myeloid leukemia treatment of non-Hodgkin lymphoma |
| gptkbp:bfsParent |
gptkb:cytarabine
|
| gptkbp:bfsLayer |
7
|